4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:血浆蛋白
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > albumin > Haematologic Technologies/Human Factor XI - Haematologic Technologies, Inc./HCXI-0150/HCXI-0150-50 µg
商品详细Haematologic Technologies/Human Factor XI - Haematologic Technologies, Inc./HCXI-0150/HCXI-0150-50 µg
Haematologic Technologies/Human Factor XI - Haematologic Technologies, Inc./HCXI-0150/HCXI-0150-50 µg
Haematologic Technologies/Human Factor XI - Haematologic Technologies, Inc./HCXI-0150/HCXI-0150-50 µg
商品编号: HCXI-0150-50µg
品牌: haemtech
市场价: ¥1720.00
美元价: 1032.00
产地: 美国(厂家直采)
公司:
产品分类: 白蛋白
公司分类: albumin
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

Factor XI is a plasma glycoprotein which circulates in a non-covalent complex with high molecular weight kininogen (1). The mature molecule is synthesized in the liver and is a two-chain homodimer with a molecular weight of approximately 160,000 (2,3). It is estimated that 5% of the total mass is attributable to carbohydrate (2). The two identical monomers have molecular weights of 80,000, and are joined together by disulfide bonds. Thus by SDS-PAGE analysis, factor XI appears as a single band both non-reduced (Mr=160,000), and reduced (Mr=80,000).

Factor XI circulates as a zymogen and requires proteolytic activation to acquire serine protease activity. The conversion of factor XI to factor XIa is catalyzed by factor XIIa, and results in cleavage of the Arg369-Ile370 bond in each monomer (3). Factor XIa consists of two NH2-terminal derived heavy chains, and two COOH-terminal derived light chains, all of which are held together by disulfide bonds. Factor XIa participates within the intrinsic pathway of coagulation by catalyzing the conversion of factor IX to factor IXa. A bleeding disorder called plasma thromboplastin antecedent deficiency results from a lack of factor XI procoagulant activity (4,5). The variable bleeding tendencies observed in factor XI deficient patients do not correlate with either factor XI activity or antigen levels. This latter observation may be related to the ability of the tissue factor/factor VIIa complex to also activate factor IX to IXa.

Historically, factor XI has been difficult to purify due to its relatively low concentration in plasma, and its susceptibility to proteolysis (6). Factor XI is purified from fresh frozen plasma that is stabilized by added inhibitors. The plasma is first treated with BaCl2 to remove the vitamin K-dependent proteins, and factor XI is then isolated by affinity chromatography. A final chromatography step on heparin sepharose yields a homogeneous preparation of intact factor XI. The finished product is supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20oC.

品牌介绍
Haematologic Technologies是一家通过ISO 9001:2015认证的公司,是一家主要制造商,专门从事旨在用于体外研究的高质量血浆蛋白的分离和表征的主要制造商。HT的重点是参与凝血级联反应的蛋白质,以及骨代谢的调节。HT产品系列包括150多种高度纯化且特性良好的蛋白质,包括酶原,酶,辅因子和抑制剂,以及单克隆和多克隆抗体的互补产品系列。还提供因子不足的血浆和定制的用于临床研究的定制采血管。提供的服务包括定制蛋白质纯化,蛋白质修饰,分析开发,合同制造和合同研究。